Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors pembrolizumab, atezolizumab, and cemiplimab in CSCC, followed by a focused discussion of recent cemiplimab trial data.
More than a thousand Australians will have access to cheaper medicines from next month under new listings to the Pharmaceutical Benefits Scheme announced by Health Minister Mark Butler.
Sanofi grants Regeneron worldwide exclusive license rights to Libtayo (cemiplimab) Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of LibtayoSanofi